Circulating anticoagulants are pathological substances which interfere with clottlng
mechanisms. Their characterization has always been more difficult than that for clotting …

The association of a circulating anticoagulant and systemic lupus erythematosus (SLE) was
first reported in 19 52 (Conley & Hartmann, 1952). The term 'lupus anticoagulant'(LA) was …

The clinical and laboratory features of 100 patients with lupus anticoagulant (LA) are
reviewed. Subjects were divided into three groups according to their age (1–5, 15–35, 45 …

Lupus anticoagulants (LA) were originally described in patients with systemic lupus
erythematosus (SLE) and clinical bleeding. Following the original description, they were …

Approximately 2% of the patients screened in our laboratories with activated partial
thromboplastin times are found to have a lupus anticoagulant. Recognition of lupus …

An acquired inhibitor of blood coagulation, similar to that described in patients with Systemic
Lupus Erythematosus (SLE), was detected during routine coagulation screening in 10 …

25 patients with lupus anticoagulant (LA) and a history of thrombosis are described and the
cases reported in the literature with this association are reviewed. From the combined data it …

To define clinical and laboratory characteristics of the lupus anticoagulant (LA), we reviewed
our experience (219 subjects). Subjects were divided into group A, those with the LA and the …

The term lupus anticoagulant (LAC) refers to antiphospholipid antibodies assessed by
means of phospholipid-dependent coagulation tests. About two-thirds of LAC-positive …

Methods In order to examine the sensitivity of various tests and reagents for the detection of
the anticoagulant, three laboratories collected plasma samples from 24 patients previously …